drugset / Trial / NCT02529839

Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)

NCT02529839

Unknown 20 enrolled Hadassah Medical Organization
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of an immunoablative nonmyeloablative conditioning protocol for autologous bone marrow transplantation in patients with Multiple Sclerosis. Patients meeting inclusion and exclusion criteria will start an immunoablative nonmyeloablative conditioning regimen followed by autologous bone marrow transplantation. Patients will be followed for one year by a neurologist to evaluate the course of the disease after treatment.

Timeline

Start
2015-10
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Background Alemtuzumab Monoclonal antibody 24 mg Subcutaneous
Background Cyclophosphamide Other / unclassified 50 mg/kg
Background Fludarabine Small molecule 30 mg/m2

Indications